niacin has been researched along with Renal Insufficiency, Chronic in 14 studies
Niacin: A water-soluble vitamin of the B complex occurring in various animal and plant tissues. It is required by the body for the formation of coenzymes NAD and NADP. It has PELLAGRA-curative, vasodilating, and antilipemic properties.
vitamin B3 : Any member of a group of vitamers that belong to the chemical structural class called pyridines that exhibit biological activity against vitamin B3 deficiency. Vitamin B3 deficiency causes a condition known as pellagra whose symptoms include depression, dermatitis and diarrhea. The vitamers include nicotinic acid and nicotinamide (and their ionized and salt forms).
nicotinic acid : A pyridinemonocarboxylic acid that is pyridine in which the hydrogen at position 3 is replaced by a carboxy group.
Renal Insufficiency, Chronic: Conditions in which the KIDNEYS perform below the normal level for more than three months. Chronic kidney insufficiency is classified by five stages according to the decline in GLOMERULAR FILTRATION RATE and the degree of kidney damage (as measured by the level of PROTEINURIA). The most severe form is the end-stage renal disease (CHRONIC KIDNEY FAILURE). (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002)
| Excerpt | Relevance | Reference |
|---|---|---|
| " In a randomized controlled trial of patients with dyslipidemia assigned to either extended release niacin (ERN) alone, ERN combined with the selective prostaglandin D2 receptor subtype 1 inhibitor laropiprant (ERN-L) or placebo, niacin lowered serum phosphorus; however, it is not known if it lowers FGF23 concentrations." | 5.19 | Effect of niacin on FGF23 concentration in chronic kidney disease. ( Bostom, A; Ix, JH; Rao, M; Steffes, M, 2014) |
| " However, niacin can cause flushing and niacinamide probably cause thrombocytopenia." | 4.90 | Benefits and harm of niacin and its analog for renal dialysis patients: a systematic review and meta-analysis. ( Feng, L; He, YM; Huo, DM; Liao, YH; Yang, ZH, 2014) |
| "Early-stage detection of chronic kidney diseases (CKD) is important to treatment that may slow and occasionally halt CKD progression." | 3.01 | The complexity of nicotinamide adenine dinucleotide (NAD), hypoxic, and aryl hydrocarbon receptor cell signaling in chronic kidney disease. ( Curran, CS; Kopp, JB, 2023) |
| "This review summarizes the role of hyperlipidemia in ASCVD and treatment strategies for hyperlipidemia in the CKD population." | 2.72 | Concepts and Controversies: Lipid Management in Patients with Chronic Kidney Disease. ( Bangalore, S; Chaudhry, R; Costa, SP; Lyubarova, R; Mathew, RO; Rosenson, RS; Sidhu, MS, 2021) |
| " As for safety end points (including mortality, adverse events, and all-cause discontinuation), almost all agents were equivalent in term of mortality and all-cause discontinuation except in the comparison between iron-based phosphate-binding agents and placebo." | 2.58 | Comparative Efficacy and Safety of Phosphate Binders in Hyperphosphatemia Patients With Chronic Kidney Disease. ( Bai, Q; Guo, H; Li, Y; Liu, H; Yang, X; Zhang, X, 2018) |
| "Niacin has a favorable unique impact on factors affecting the rate of glomerular filtration rate decline, including high-density lipoprotein (HDL) particle number and function, triglyceride levels, oxidant stress, inflammation and endothelial function, and lowering of serum phosphorus levels by reducing dietary phosphorus absorption in the gastrointestinal tract." | 2.52 | Niacin and progression of CKD. ( Kalantar-Zadeh, K; Kashyap, ML; Kovesdy, CP; Moradi, H; Streja, DA; Streja, E, 2015) |
| "Hyperphosphatemia is thought to be a central-risk factor for CKD-MBD." | 1.42 | Niacin and Chronic Kidney Disease. ( Masuda, M; Miyamoto, K; Segawa, H; Takeda, E; Taketani, Y; Tatsumi, S; Yamamoto, H; Yamanaka-Okumura, H, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (7.14) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 9 (64.29) | 24.3611 |
| 2020's | 4 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Kędzierska-Kapuza, K | 1 |
| Szczuko, U | 1 |
| Stolińska, H | 1 |
| Bakaloudi, DR | 1 |
| Wierzba, W | 1 |
| Szczuko, M | 1 |
| Curran, CS | 1 |
| Kopp, JB | 1 |
| Kalantari, S | 1 |
| Chashmniam, S | 1 |
| Nafar, M | 1 |
| Samavat, S | 1 |
| Rezaie, D | 1 |
| Dalili, N | 1 |
| Mathew, RO | 2 |
| Rosenson, RS | 1 |
| Lyubarova, R | 1 |
| Chaudhry, R | 1 |
| Costa, SP | 1 |
| Bangalore, S | 1 |
| Sidhu, MS | 1 |
| Yang, X | 1 |
| Bai, Q | 1 |
| Li, Y | 1 |
| Liu, H | 1 |
| Guo, H | 1 |
| Zhang, X | 1 |
| Drüeke, TB | 1 |
| Massy, ZA | 1 |
| Streja, E | 2 |
| Streja, DA | 2 |
| Soohoo, M | 1 |
| Kleine, CE | 1 |
| Hsiung, JT | 1 |
| Park, C | 1 |
| Moradi, H | 2 |
| Khoueiry, G | 1 |
| Abdallah, M | 1 |
| Saiful, F | 1 |
| Abi Rafeh, N | 1 |
| Raza, M | 1 |
| Bhat, T | 1 |
| El-Sayegh, S | 1 |
| Kalantar-Zadeh, K | 2 |
| Lafferty, J | 1 |
| He, YM | 1 |
| Feng, L | 1 |
| Huo, DM | 1 |
| Yang, ZH | 1 |
| Liao, YH | 1 |
| Rao, M | 1 |
| Steffes, M | 1 |
| Bostom, A | 1 |
| Ix, JH | 2 |
| Kalil, RS | 1 |
| Wang, JH | 1 |
| de Boer, IH | 1 |
| Asif, A | 1 |
| Shi, X | 1 |
| Boden, WE | 1 |
| Kovesdy, CP | 1 |
| Kashyap, ML | 1 |
| Taketani, Y | 1 |
| Masuda, M | 1 |
| Yamanaka-Okumura, H | 1 |
| Tatsumi, S | 1 |
| Segawa, H | 1 |
| Miyamoto, K | 1 |
| Takeda, E | 1 |
| Yamamoto, H | 1 |
| KNICK, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Evaluate the Lipid-Altering Efficacy, Safety and Tolerability of MK0524A in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia[NCT00269204] | Phase 3 | 1,620 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
8 reviews available for niacin and Renal Insufficiency, Chronic
| Article | Year |
|---|---|
Demand for Water-Soluble Vitamins in a Group of Patients with CKD versus Interventions and Supplementation-A Systematic Review.
Topics: Ascorbic Acid; Dietary Supplements; Folic Acid; Humans; Kidney Failure, Chronic; Niacin; Renal Dialy | 2023 |
The complexity of nicotinamide adenine dinucleotide (NAD), hypoxic, and aryl hydrocarbon receptor cell signaling in chronic kidney disease.
Topics: Basic Helix-Loop-Helix Transcription Factors; Humans; Hypoxia; Ischemia; NAD; Niacin; Receptors, Ary | 2023 |
Concepts and Controversies: Lipid Management in Patients with Chronic Kidney Disease.
Topics: Atherosclerosis; Ezetimibe; Fibric Acids; Glomerular Filtration Rate; Humans; Hydroxymethylglutaryl- | 2021 |
Comparative Efficacy and Safety of Phosphate Binders in Hyperphosphatemia Patients With Chronic Kidney Disease.
Topics: Bile Acids and Salts; Calcium; Calcium Compounds; Chelating Agents; Humans; Hyperphosphatemia; Iron; | 2018 |
Precision Medicine and Personalized Management of Lipoprotein and Lipid Disorders in Chronic and End-Stage Kidney Disease.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Dyslipidemias; Ezetimibe; Fenofibrate; Humans; Hy | 2018 |
High-density lipoprotein in uremic patients: metabolism, impairment, and therapy.
Topics: Acetamides; Acetates; Acetyl-CoA C-Acetyltransferase; Anti-Inflammatory Agents; Anticholesteremic Ag | 2014 |
Benefits and harm of niacin and its analog for renal dialysis patients: a systematic review and meta-analysis.
Topics: Flushing; Humans; Lipoproteins, HDL; Niacin; Niacinamide; Phosphorus; Randomized Controlled Trials a | 2014 |
Niacin and progression of CKD.
Topics: Comorbidity; Coronary Artery Disease; Disease Progression; Endothelium, Vascular; Humans; Hypolipide | 2015 |
2 trials available for niacin and Renal Insufficiency, Chronic
| Article | Year |
|---|---|
Effect of niacin on FGF23 concentration in chronic kidney disease.
Topics: Aged; Calcium; Delayed-Action Preparations; Double-Blind Method; Drug Therapy, Combination; Dyslipid | 2014 |
Effect of extended-release niacin on cardiovascular events and kidney function in chronic kidney disease: a post hoc analysis of the AIM-HIGH trial.
Topics: Aged; Cardiovascular Diseases; Cause of Death; Cholesterol, HDL; Delayed-Action Preparations; Drug T | 2015 |
4 other studies available for niacin and Renal Insufficiency, Chronic
| Article | Year |
|---|---|
A Noninvasive Urine Metabolome Panel as Potential Biomarkers for Diagnosis of T Cell-Mediated Renal Transplant Rejection.
Topics: Acute Disease; Adenosine Diphosphate; Adult; Biomarkers; Cholesterol Esters; Cross-Sectional Studies | 2020 |
Lowering Expectations with Niacin Treatment for CKD-MBD.
Topics: Chronic Kidney Disease-Mineral and Bone Disorder; Humans; Hyperphosphatemia; Minerals; Motivation; N | 2018 |
Niacin and Chronic Kidney Disease.
Topics: Biological Transport; Bone Diseases; Cardiovascular Diseases; Dyslipidemias; Humans; Hyperphosphatem | 2015 |
[Nicotinic acid therapy of anuric disorders in acute & chronic renal insufficiency].
Topics: Acute Kidney Injury; Anuria; Humans; Kidney Diseases; Niacin; Nicotinic Acids; Renal Insufficiency, | 1959 |